Amrubicin Receives FDA Fast Track Designation For The Treatment Of Small Cell Lung Cancer After First-Line Chemotherapy

 06.09.2008 06:13   medicalnewstoday.com

Celgene Corporation (NASDAQ: CELG) announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.

World Cancer